Bryan T Mayer1, Sujatha Srinivasan1, Tina L Fiedler1, Jeanne M Marrazzo2, David N Fredricks3, Joshua T Schiffer4. 1. Vaccine and Infectious Disease Division. 2. Department of Medicine. 3. Vaccine and Infectious Disease Division Clinical Research Division, Fred Hutchinson Cancer Research Center Department of Medicine Department of Microbiology, University of Washington, Seattle. 4. Vaccine and Infectious Disease Division Clinical Research Division, Fred Hutchinson Cancer Research Center Department of Medicine.
Abstract
BACKGROUND: Bacterial vaginosis (BV) is a common polymicrobial disease associated with numerous negative reproductive health outcomes, including an increased risk of human immunodeficiency virus acquisition. BV is treatable with antibiotics, but relapse is common. A more detailed understanding of bacterial dynamics during antibiotic therapy for BV could identify conditions that favor establishment, maintenance, and eradication of BV-associated bacterial species, thereby improving treatment outcomes. METHODS: We used mathematical models to analyze daily quantitative measurements of 11 key bacterial species during metronidazole treatment for 15 cases of BV. RESULTS: We identified complete reorganization of vaginal bacterial composition within a day of initiating therapy. Although baseline bacterial levels predicted a longer time to clearance, all anaerobic species were eliminated rapidly within a median of 3 days. However, reemergence of BV-associated species was common following treatment cessation. Gardnerella vaginalis, a facultative anaerobe, was cleared more slowly than anaerobic BV-associated species, and levels of G. vaginalis often rebounded during treatment. We observed gradual Lactobacillus species growth, indicating that untargeted microbes fill the transient vacuum formed during treatment. CONCLUSIONS: Under antibiotic pressure, the human microbiome can undergo rapid shifts on a scale of hours. When treatment is stopped, BV-associated bacteria quickly reemerge, suggesting a possible role for intermittent prophylactic treatment.
BACKGROUND:Bacterial vaginosis (BV) is a common polymicrobial disease associated with numerous negative reproductive health outcomes, including an increased risk of human immunodeficiency virus acquisition. BV is treatable with antibiotics, but relapse is common. A more detailed understanding of bacterial dynamics during antibiotic therapy for BV could identify conditions that favor establishment, maintenance, and eradication of BV-associated bacterial species, thereby improving treatment outcomes. METHODS: We used mathematical models to analyze daily quantitative measurements of 11 key bacterial species during metronidazole treatment for 15 cases of BV. RESULTS: We identified complete reorganization of vaginal bacterial composition within a day of initiating therapy. Although baseline bacterial levels predicted a longer time to clearance, all anaerobic species were eliminated rapidly within a median of 3 days. However, reemergence of BV-associated species was common following treatment cessation. Gardnerella vaginalis, a facultative anaerobe, was cleared more slowly than anaerobic BV-associated species, and levels of G. vaginalis often rebounded during treatment. We observed gradual Lactobacillus species growth, indicating that untargeted microbes fill the transient vacuum formed during treatment. CONCLUSIONS: Under antibiotic pressure, the human microbiome can undergo rapid shifts on a scale of hours. When treatment is stopped, BV-associated bacteria quickly reemerge, suggesting a possible role for intermittent prophylactic treatment.
Authors: B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho Journal: Lancet Date: 1999-11-20 Impact factor: 79.321
Authors: Harold C Wiesenfeld; Sharon L Hillier; Marijane A Krohn; Daniel V Landers; Richard L Sweet Journal: Clin Infect Dis Date: 2003-02-07 Impact factor: 9.079
Authors: Catriona S Bradshaw; Anna N Morton; Jane Hocking; Suzanne M Garland; Margaret B Morris; Lorna M Moss; Leonie B Horvath; Irene Kuzevska; Christopher K Fairley Journal: J Infect Dis Date: 2006-04-26 Impact factor: 5.226
Authors: Harold C Wiesenfeld; Sharon L Hillier; Marijane A Krohn; Antonio J Amortegui; R Phillips Heine; Daniel V Landers; Richard L Sweet Journal: Obstet Gynecol Date: 2002-09 Impact factor: 7.661
Authors: S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao Journal: N Engl J Med Date: 1995-12-28 Impact factor: 91.245
Authors: Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young Journal: Infect Immun Date: 2009-03-23 Impact factor: 3.441
Authors: A R Sitarik; S Havstad; A M Levin; S V Lynch; K E Fujimura; D R Ownby; C C Johnson; G Wegienka Journal: Indoor Air Date: 2018-03-13 Impact factor: 5.770
Authors: Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Melinda A B Petrina; Lisa A Cosentino; Harold C Wiesenfeld; Toni Darville; Sharon L Hillier Journal: Anaerobe Date: 2019-02-10 Impact factor: 3.331
Authors: Ian B Stanaway; James C Wallace; Ali Shojaie; William C Griffith; Sungwoo Hong; Carly S Wilder; Foad H Green; Jesse Tsai; Misty Knight; Tomomi Workman; Eric M Vigoren; Jeffrey S McLean; Beti Thompson; Elaine M Faustman Journal: Appl Environ Microbiol Date: 2016-12-30 Impact factor: 4.792
Authors: Michael Loesche; Sue E Gardner; Lindsay Kalan; Joseph Horwinski; Qi Zheng; Brendan P Hodkinson; Amanda S Tyldsley; Carrie L Franciscus; Stephen L Hillis; Samir Mehta; David J Margolis; Elizabeth A Grice Journal: J Invest Dermatol Date: 2016-08-24 Impact factor: 8.551
Authors: Sujatha Srinivasan; Matthew M Munch; Maria V Sizova; Tina L Fiedler; Christina M Kohler; Noah G Hoffman; Congzhou Liu; Kathy J Agnew; Jeanne M Marrazzo; Slava S Epstein; David N Fredricks Journal: J Infect Dis Date: 2016-08-15 Impact factor: 5.226